Cita APA

MP, G., M, T., J, H., J, S., O, T., IH, P., . . . SRD, J. (2024). Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HRD, HER2L advanced breast cancer: Final overall survival results of MONARCH 3.

Citación estilo Chicago

MP, Goetz, et al. Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor As Initial Therapy for HRD, HER2L Advanced Breast Cancer: Final Overall Survival Results of MONARCH 3. 2024.

Cita MLA

MP, Goetz, et al. Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor As Initial Therapy for HRD, HER2L Advanced Breast Cancer: Final Overall Survival Results of MONARCH 3. 2024.